KNSA

Kiniksa Pharmaceuticals Stock Price

21.89
1.32 (6.42%)
Upgrade to Real-Time
Afterhours (Closed)
21.89
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Kiniksa Pharmaceuticals Ltd KNSA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.32 6.42% 21.89 19:32:17
Open Price Low Price High Price Close Price Prev Close
21.29 21.113 22.20 21.89 20.57
Bid Price Ask Price Spread News
21.90 22.70 0.80 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,593 422,238 $ 21.69 $ 9,157,514 348,511 10.30 - 33.00
Last Trade Time Type Quantity Stock Price Currency
18:48:14 formt 100 $ 21.89 USD

Kiniksa Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.49B 68.08M 28.06M $ - $ - -3.01 -7.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -100.00k 0.30%

more financials information »

Kiniksa Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KNSA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week23.9724.7019.829221.98429,149-2.08-8.68%
1 Month20.3024.7019.6122.06357,0581.597.83%
3 Months17.2124.7016.6520.12342,7044.6827.19%
6 Months17.6724.7014.5118.30382,3684.2223.88%
1 Year18.3833.0010.3018.99352,1343.5119.1%
3 Years24.4533.005.0117.60221,407-2.56-10.47%
5 Years24.4533.005.0117.60221,407-2.56-10.47%

Kiniksa Pharmaceuticals Description

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, KPL-045, KPL-404 are other monoclonal antibodies.


Your Recent History
NASDAQ
KNSA
Kiniksa Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.